# Impact of epiretinal membrane peeling on steroid dependency in uveitic eyes: a retrospective analysis

**Authors:** Verena Schöneberger, Julia Schirrwagen, Claudia Brockmann, Thomas A. Fuchsluger, Friederike Schaub

PMC · DOI: 10.1186/s40942-025-00712-2 · International Journal of Retina and Vitreous · 2025-07-29

## TL;DR

This study examines if removing epiretinal membranes in uveitic eyes reduces the need for steroids, finding mixed results with some patients benefiting but others not.

## Contribution

The study provides new insights into the relationship between epiretinal membrane peeling and steroid dependency in uveitic eyes.

## Key findings

- Approximately 28.4% of patients experienced a reduction in steroid therapy after surgery.
- Postoperative retinal thickness and macular volume decreased significantly.
- A subset of patients required intensified therapy due to postoperative inflammation or CME recurrence.

## Abstract

Secondary epiretinal membranes (sERM) are common in uveitis and often associated with cystoid macular edema (CME), which increases the need for anti-inflammatory treatment. While surgical removal can improve anatomical and visual outcomes, its effect on intraocular inflammation and steroid requirement remains unclear. This study evaluates whether vitrectomy with ERM peeling can reduce the need for postoperative steroid therapy in uveitic eyes.

This retrospective single-center study reviewed 67 eyes of 67 patients with history of uveitis who underwent sERM peeling between 11/2002 and 04/2023. Demographic data, uveitis classification (SUN), spectral domain optical coherence tomography (SD-OCT) findings, and pre-/postoperative steroid requirements were analyzed. Statistical significance testing was performed using a paired two-tailed t-test.

Of the 67 eyes, 50.7% were right eyes, and 65.7% of patients were female. Mean age at timepoint of surgery was 63.1 ± 13.6 years, with 53.7% phakic eyes. Uveitis was classified as anterior (17.9%), intermediate (44.8%), posterior (31.3%), and panuveitis (6.0%). Steroid therapy was reduced in 28.4% of patients, remained unchanged in 56.7%, and increased in 14.9%. Preoperatively, cystoid macular edema (CME) was present in 41.4% of the 58 available SD-OCT scans. Postoperatively, retinal thickness, macular volume, and total retinal volume decreased significantly (p < 0.001). Postoperative CME was found in 31.3% in first postoperative SD-OCT and was newly observed in 6.0%, while 62.7% showed no CME.

ERM peeling in uveitic eyes does not guarantee functional improvement or a consistent reduction in steroid dependency. While approximately one-third of patients benefited from reduced steroid use—particularly those with preoperative CME—the majority showed no change, and a subset required intensified therapy due to postoperative inflammation or CME recurrence. Careful patient selection remains essential.

## Linked entities

- **Diseases:** uveitis (MONDO:0020283), cystoid macular edema (MONDO:0007935)

## Full-text entities

- **Genes:** PVR (PVR cell adhesion molecule) [NCBI Gene 5817] {aka CD155, HVED, NECL5, Necl-5, PVS, TAGE4}
- **Diseases:** Uveitis (MESH:D014605), vitreous floaters (MESH:C000726608), lymphoma (MESH:D008223), aphakia (MESH:D001035), yersiniosis (MESH:D015009), panuveitis (MESH:D015864), borreliosis (MESH:D008193), CME (MESH:D008269), Secondary epiretinal membrane (MESH:D019773), inflammatory edema (MESH:D004487), toxoplasmosis (MESH:D014123), proliferative diabetic retinopathy (OMIM:603933), metamorphopsia (MESH:D014786), chlamydia (MESH:D002690), BSS (MESH:D013651), anterior chamber or vitreous inflammation (MESH:D007249), posterior uveitis (MESH:D015866), ILM (MESH:D015433), uveitic eyes (MESH:D005134), diabetic retinopathy (MESH:D003930), macular hole (MESH:D012167), retinal detachment (MESH:D012163), Cataract (MESH:D002386), Proliferative vitreoretinopathy (MESH:D018630), steroid (MESH:D016114)
- **Chemicals:** fluocinolone acetonide (MESH:D005446), triamcinolone (MESH:D014221), SF6 (MESH:D013459), Steroid (MESH:D013256), BSS (-), prednisone (MESH:D011241), silicone oil (MESH:D012827), prednisolone acetate (MESH:C009935), dexamethasone (MESH:D003907)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12306005/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12306005/full.md

## References

7 references — full list in the complete paper: https://tomesphere.com/paper/PMC12306005/full.md

---
Source: https://tomesphere.com/paper/PMC12306005